About Innovate Biopharmaceuticals

Innovate, a privately-held clinical stage biotechnology company, is focused on developing novel gastroenterology medicines. Our pipeline includes drug candidates for Celiac Disease, an unmet need, an adult orphan indication as well as ulcerative colitis. The Company is led by a strong management team with extensive business and regulatory experience. Innovate has all global rights to the products which are backed by more than 150 patents worldwide.


Innovate is currently developing three clinical stage assets:

  • INN-202 entering phase 3 for the treatment of Celiac Disease (CeD) with fast track designation
  • INN-108 entering phase 2 for Inflammatory Bowel Disorders, mild to moderate Ulcerative Colitis (UC) and a GI orphan disease in a convenient liquid formulation
  • INN-329 entering phase 3 for Magnetic Resonance Cholangiopancreatography (MRCP)
Subscribe to Receive Innovate News and Updates By Email